|
1
|
Cmarik JL, Min H, Hegamyer G, Zhan S,
Kulesz-Martin M, Yoshinaga H, Matsuhashi S and Colburn N:
Differentially expressed protein Pdcd4 inhibits tumor
promoter-induced neoplastic transformation. Proc Natl Acad Sci USA.
96:14037–14042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang HS, Jansen AP, Nair R, Shibahara K,
Verma AK, Cmarik JL and Colburn NH: A novel transformation
suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB
or ODC transactivation. Oncogene. 20:669–676. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ding L, Zhang X, Zhao M, Qu Z, Huang S,
Dong M and Gao F: An essential role of PDCD4 in progression and
malignant proliferation of gastrointestinal stromal tumors. Med
Oncology. 29:1758–1764. 2012. View Article : Google Scholar
|
|
4
|
LaRonde-LeBlanc N, Santhanam AN, Baker AR,
Wlodawer A and Colburn NH: Structural basis for inhibition of
translation by the tumor suppressor Pdcd4. Mol Cell Biol.
27:147–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lankat-Buttgereit B and Goke R: Programmed
cell death protein 4 (pdcd4): A novel target for antineoplastic
therapy? Biol Cell. 95:515–519. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang H, Ozaki I, Mizuta T, Hamajima H,
Yasutake T, Eguchi Y, Ideguchi H, Yamamoto K and Matsuhashi S:
Involvement of programmed cell death 4 in transforming growth
factor-beta1-induced apoptosis in human hepatocellular carcinoma.
Oncogene. 25:6101–6112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y, Knosel T, Kristiansen G, Pietas A,
Garber ME, Matsuhashi S, Ozaki I and Petersen I: Loss of PDCD4
expression in human lung cancer correlates with tumour progression
and prognosis. J Pathol. 200:640–646. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wen YH, Shi X, Chiriboga L, Matsahashi S,
Yee H and Afonja O: Alterations in the expression of PDCD4 in
ductal carcinoma of the breast. Oncol Rep. 18:1387–1393.
2007.PubMed/NCBI
|
|
9
|
Wei NA, Liu SS, Leung TH, Tam KF, Liao XY,
Cheung AN, Chan KK and Ngan HY: Loss of programmed cell death 4
(Pdcd4) associates with the progression of ovarian cancer. Mol
Cancer. 8:702009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shibahara K, Asano M, Ishida Y, Aoki T,
Koike T and Honjo T: Isolation of a novel mouse gene MA-3 that is
induced upon programmed cell death. Gene. 166:297–301. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lankat-Buttgereit B and Goke R: The tumour
suppressor Pdcd4: Recent advances in the elucidation of function
and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Onishi Y and Kizaki H: Molecular cloning
of the genes suppressed in RVC lymphoma cells by topoisomerase
inhibitors. Biochem Biophysical Res Commun. 228:7–13. 1996.
View Article : Google Scholar
|
|
13
|
Azzoni L, Zatsepina O, Abebe B, Bennett
IM, Kanakaraj P and Perussia B: Differential transcriptional
regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and
IL-12 in NK and T cells. J Immunol. 161:3493–3500. 1998.PubMed/NCBI
|
|
14
|
Mundim TC, Ramos AF, Sartori R, Dode MA,
Melo EO, Gomes LF, Rumpf R and Franco MM: Changes in gene
expression profiles of bovine embryos produced in vitro, by natural
ovulation, or hormonal superstimulation. Genet Mol Res.
8:1398–1407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin X, Zhang H, Wang F, Xue J and Wen Z:
Expression and possible role of interleukin-10 receptors in
patients with adenomyosis. Eur j Obstet Gynecol Rep Biol.
161:194–198. 2012. View Article : Google Scholar
|
|
16
|
Lin SL, Yan LY, Zhang XT, Yuan J, Li M,
Qiao J, Wang ZY and Sun QY: ER-alpha36, a variant of ER-alpha,
promotes tamoxifen agonist action in endometrial cancer cells via
the MAPK/ERK and PI3K/Akt pathways. PLoS One. 5:e90132010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Tan X, Wang Z, Li Y, Gao M, Li Y,
Fang Z, Sun Y, Zhang L, Wang X and Wei Z: Down-regulation of tumor
suppressor PDCD4 expression in endometrium of adenomyosis patients.
Curr Res Transl Med. 64:123–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li N, Wang J, Zhang N, Zhuang M, Zong Z,
Zou J, Li G, Wang X, Zhou H, Zhang L and Shi Y: Cross-talk between
TNF-α and IFN-γ signaling in induction of B7-H1 expression in
hepatocellular carcinoma cells. Cancer Immunol Immunother. 271–283.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pant A, Lee II, Lu Z, Rueda BR, Schink J
and Kim JJ: Inhibition of AKT with the orally active allosteric AKT
inhibitor, MK-2206, sensitizes endometrial cancer cells to
progestin. PLoS One. 7:e415932012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nabilsi NH, Broaddus RR, McCampbell AS, Lu
KH, Lynch HT, Chen LM and Loose DS: Sex hormone regulation of
survivin gene expression. J Endocrinol. 207:237–243. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bischof P, Krahenbuhl C and Desaulles PA:
Elucidation of the mechanism responsible for the luteolytic effect
of oestradiol during pseudogestation in the rat. Experientia.
30:1101–1102. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Knobil E: Hormonal control of the
menstrual cycle and ovulation in the rhesus monkey. Acta Endocrinol
Suppl (Copenh). 166:137–144. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao Y, Gong P, Chen Y, Nwachukwu JC,
Srinivasan S, Ko C, Bagchi MK, Taylor RN, Korach KS, Nettles KW, et
al: Dual suppression of estrogenic and inflammatory activities for
targeting of endometriosis. Sci Transl Med. 7:271ra92015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stadel BV: Estrogen therapy and
endometrial carcinoma. Am J Obstet Gynecol. 125:571–573. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang Z, Yang S, Lydon JP, DeMayo F, Tamura
M, Gurates B and Bulun SE: Intact progesterone receptors are
essential to counteract the proliferative effect of estradiol in a
genetically engineered mouse model of endometriosis. Ferti Steril.
82:673–678. 2004. View Article : Google Scholar
|
|
26
|
Cooke PS, Buchanan DL, Young P,
Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW,
Kiesel L and Nap A: Stromal estrogen receptors mediate mitogenic
effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA.
94:6535–6540. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Adur MK, Kannan A, Davila J, Zhao Y,
Nowak RA, Bagchi MK, Bagchi IC and Li Q: Progesterone alleviates
endometriosis via inhibition of uterine cell proliferation,
inflammation and angiogenesis in an immunocompetent mouse model.
PLoS One. 11:e01653472016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dunselman GA, Vermeulen N, Becker C,
Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW,
Kiesel L, Nap A, et al: ESHRE guideline: Management of women with
endometriosis. Hum Reprod. 29:400–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mounsey AL, Wilgus A and Slawson DC:
Diagnosis and management of endometriosis. Am Fam Physician.
74:594–600. 2006.PubMed/NCBI
|
|
30
|
Vercellini P, Vigano P, Somigliana E and
Fedele L: Endometriosis: Pathogenesis and treatment. Nat Rev
Endocrinol. 10:261–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schweppe KW: Current place of progestins
in the treatment of endometriosis-related complaints. Gynecol
Endocrinol. 6:22–28. 2001. View Article : Google Scholar
|
|
32
|
Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke
WM, Ananth CV, Neugut AI, Hershman DL and Wright JD: All-cause
mortality in young women with endometrial cancer receiving
progesterone therapy. Am J Obstet Gynecol. 217:669.e1–669.e13.
2017. View Article : Google Scholar
|
|
33
|
Xie M, Zhu X, Liu Z, Shrubsole M, Varma V,
Mayer IA, Dai Q, Chen Q and You S: Membrane progesterone receptor
alpha as a potential prognostic biomarker for breast cancer
survival: A retrospective study. PLoS One. 7:e351982012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thomas P: Characteristics of membrane
progestin receptor alpha (mPRalpha) and progesterone membrane
receptor component 1 (PGMRC1) and their roles in mediating rapid
progestin actions. Front Neuroendocrinol. 29:292–312. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dressing GE and Thomas P: Identification
of membrane progestin receptors in human breast cancer cell lines
and biopsies and their potential involvement in breast cancer.
Steroids. 72:111–116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sleiter N, Pang Y, Park C, Horton TH, Dong
J, Thomas P and Levine JE: Progesterone receptor A (PRA) and
PRB-independent effects of progesterone on gonadotropin-releasing
hormone release. Endocrinology. 150:3833–3844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu Y, Rice CD, Pang Y, Pace M and Thomas
P: Cloning, expression, and characterization of a membrane
progestin receptor and evidence it is an intermediary in meiotic
maturation of fish oocytes. Proc Natl Acad Sci USA. 100:2231–2236.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Piasecka D, Skladanowski AC, Kordek R,
Romanska HM and Sadej R: Aspects of progesterone receptor (PR)
activity regulation-impact on breast cancer progression. Postepy
Biochem. 61:198–206. 2015.PubMed/NCBI
|
|
39
|
Jiang LP, He CY and Zhu ZT: Role of
microRNA-21 in radiosensitivity in non-small cell lung cancer cells
by targeting PDCD4 gene. Oncotarget. 8:23675–23689. 2017.PubMed/NCBI
|
|
40
|
Dorrello NV, Peschiaroli A, Guardavaccaro
D, Colburn NH, Sherman NE and Pagano M: S6K1- and betaTRCP-mediated
degradation of PDCD4 promotes protein translation and cell growth.
Science. 314:467–471. 2006. View Article : Google Scholar : PubMed/NCBI
|
